Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release first quarter 2021 financial results after market close on Monday, May 10, 2021. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, May 11, 2021 to discuss the financial results and to provide a corporate update.

Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Why Is Catalyst (CPRX) Up 8.9% Since Last Earnings Report?

CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that its Board of Directors has authorized the repurchase of up to $40 million of shares of Catalyst's outstanding common stock.

Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program

To increase one's chances of beating the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.

3 Magic Formula Stocks for the Value Investor

Catalyst Pharmaceuticals reported its Q4 results highlighted by record revenues from its Firdapse drug, as the only FDA-approved treatment of LEMS disease. The company expects momentum to continue with the end of the pandemic allowing for new patients to be diagnosed and receive a prescription.

Catalyst Pharmaceuticals Inc.: Attractive Value Supported By New Growth Opportunities

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2020 Results - Earnings Call Transcript

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and 3.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Beats Q4 Earnings and Revenue Estimates

- Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Athenex

Bellus Health Inc

New Age Beverages

OPKO Health

Spectrum Pharma

Uranium Energy

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

7 Penny Stocks That Wall Street Thinks Are Undervalued

CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release fourth quarter and year-end 2020 financial results after market close on Monday, March 15, 2021. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, March 16, 2021 to discuss the financial results and to provide a corporate update.

Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021

CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support for Rare Disease Day 2021.

Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021

Ambev

Yamana Gold

Banco Bradesco

NatWest Group plc 

W&T Offshore

BGC Partners

Penny stocks are low price for a reason. Most presume they're destined for bankruptcy.

7 Penny Stock Companies That Actually Make Money

TherapeuticsMD

Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recommended” by members of the WallStreetBets message board on Reddit and traded heavily through online brokerage firm Robinhood.

Catalyst Pharma, TherapeuticsMD May Be Next WallStreetBets Targets

OrganiGram Holdings Inc.

Vaxart

Investors can start the new year off right by digging into these three small but fiery stocks.

3 Top Small-Cap Stocks to Buy in January

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans

NRG Energy

Tyson Foods

Investors focused on assets with high returns may want to consider the following non-cyclical stocks, as their earnings yields (as calculated through Joel Greenblatt's method) are outperforming the S&P 500, which is a benchmark index for the U.S. market.

3 Non-Cyclical Stocks to Consider

CORAL GABLES, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced an expansion in its strategic priorities related to portfolio planning and research and development. Catalyst also provided preliminary net revenues and cash on hand for fiscal-year 2020, as well as an update on product development activities and current litigation.

Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update

Catalyst Pharma is a commercial-stage small biotech with a highly profitable orphan drug Firdapse for adult LEMS patients in the US market. Catalyst Pharma is trading at PE ratio of 5 and price-to-sales ratio of 2.96. The company exited Q3 with $127M in cash and no debt.

Catalyst Pharmaceuticals: Attractive Valuation Has Priced In Risks

Co-Diagnostics

QuidelOrtho Corp

Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profitability tabs runs a significant gamut of the information properly considered in performing due diligence on a stock.

A+ Top Quant Rated Healthcare Stocks For Value, Growth, And Profitability

Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 5.5%

BioDelivery Sciences

BioMarin Pharmaceutical

Innoviva

Novavax

Vertex Pharmaceuticals

Voyager Therapeutics

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Biotech Stocks for Q1 2021

Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report?

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

News for Catalyst Pharmaceuticals Stock (CPRX)